🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

103 results for “GlaxoSmithKline” Clear

  1. 0.9% Sodium Chloride for Injection, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion., JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline Biologicals S.A.

    Lung Cancer, Non-Small Cell

    phase 3 small molecule active

    1 trial

  2. A multi-centre, single arm, open-label extension study to evaluate the long-term safety of GSK3511294 (Depemokimab) in adult and adolescent participants with severe asthma with an eosinophilic phenotype from studies 206713 or 213744

    GlaxoSmithKline Biologicals S.A.

    Severe asthma with an eosinophilic phenotype

    phase 3 other active

    1 trial

  3. A placebo matching Mepolizumab, Nucala 100 mg solution for injection in pre-filled syringe, A placebo matching Depemokimab, GSK3511294, Placebo for benralizumab for clinical trials is a sterile liquid solution presented in an accessorized prefilled syringe (apfs) for subcutaneous injection, Nucala 100 mg solution for injection in pre-filled syringe, Fasenra 30 mg solution for injection in pre-filled syringe

    GlaxoSmithKline Biologicals S.A.

    Severe asthma with an eosinophilic phenotype

    phase 3 small molecule active

    1 trial

  4. Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted)

    GlaxoSmithKline Biologicals S.A.

    Respiratory Syncytial Virus Infections

    phase 3 small molecule active

    1 trial

  5. Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted), Comirnaty Omicron XBB.1.5 30 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine

    GlaxoSmithKline Biologicals S.A.

    Respiratory Syncytial Virus Infections

    phase 3 small molecule active

    1 trial

  6. Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted)

    GlaxoSmithKline Biologicals S.A.

    Respiratory Syncytial Virus Infections

    phase 3 small molecule active

    1 trial

  7. Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted)

    GlaxoSmithKline Biologicals S.A.

    Respiratory Syncytial Virus Infections

    phase 3 small molecule active

    1 trial

  8. Benlysta 200 mg solution for injection in pre-filled pen.

    GlaxoSmithKline Biologicals S.A.

    connective tissue diseases

    phase 3 small molecule active

    1 trial

  9. Benlysta 200 mg solution for injection in pre-filled syringe., Placebo for Belimumab Solution for Injection, 200 mg/mL. The placebo for Belimumab Solution for Injection, 200 mg/mL is provided as a sterile solution for subcutaneous (SC) injection in single-use prefilled syringes.

    GlaxoSmithKline Biologicals S.A.

    Lung Diseases, Interstitial

    phase 3 small molecule active

    1 trial

  10. Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed), Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed), Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed), Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed)

    GlaxoSmithKline Biologicals S.A.

    Invasive meningococcal disease (IMD)

    phase 3 small molecule active

    1 trial

  11. Dexa 8 mg inject JENAPHARM Injektionslösung, VELCADE 3.5 mg powder for solution for injection, Dexamethason 8 mg GALEN® Tabletten, Dexamethasone Tablets BP 2.0mg, Dexamethasone 2mg Tablets, Dexa-ratiopharm® 8 mg Injektionslösung, DARZALEX 20 mg/mL concentrate for solution for infusion, Dexamethason 8 mg JENAPHARM®

    GlaxoSmithKline Biologicals S.A.

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  12. Dexamethason 8 mg GALEN® Tabletten, Imnovid 1 mg hard capsules, Dexamethasone 2mg Tablets, Dexamethason 8 mg JENAPHARM®, Dexamethasone Tablets BP 2.0mg, Imnovid 4 mg hard capsules

    GlaxoSmithKline Biologicals S.A.

    Relapsed/Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  13. Expanded access program for mepolizumab in subjects with hypereosinophilic syndrome.

    GlaxoSmithKline Biologicals S.A.

    Hypereosinophilic Syndrome

    phase 3 other active

    1 trial

  14. Imnovid 3 mg hard capsules, Imnovid 4 mg hard capsules, Dexamethasone Tablets BP 2.0mg, Dexamethason 8 mg GALEN® Tabletten, Imnovid 2 mg hard capsules, Dexamethason 8 mg JENAPHARM®, Dexamethasone 2mg Tablets, Imnovid 1 mg hard capsules, VELCADE 3.5 mg powder for solution for injection

    GlaxoSmithKline Biologicals S.A.

    Relapsed/Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  15. JEMPERLI 500 mg concentrate for solution for infusion, Docetaxel Hikma 20 mg/1 ml Konzentrat zur Herstellung einer Infusionslösung, Docetaxel Hikma 80 mg/4 ml Konzentrat zur Herstellung einer Infusionslösung, Docetaxel Hikma 160 mg/8 ml Konzentrat zur Herstellung einer Infusionslösung

    GlaxoSmithKline Biologicals S.A.

    Lung Cancer, Non-Small Cell

    phase 3 small molecule active

    1 trial

  16. Locally sourced sterile 0.9% (w/v) sodium chloride, JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline Biologicals S.A.

    Neoplasms, Head and Neck

    phase 3 small molecule active

    1 trial

  17. MEPOLIZUMAB

    GlaxoSmithKline Biologicals S.A.

    Hypereosinophilic syndrome (HES)

    phase 3 small molecule active

    1 trial

  18. Niraparib Placebo Tablets

    GlaxoSmithKline Biologicals S.A.

    Neoplasms, Breast

    phase 3 small molecule active

    1 trial

  19. Niraparib Placebo Tablets, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    GlaxoSmithKline Biologicals S.A.

    Lung Cancer, Non-Small Cell

    phase 3 small molecule active

    1 trial

  20. Novolizer Salbutamol 100 microgrammes/dose, poudre pour inhalation, Sterile 0.9% (w/v) sodium chloride solution in single-use PFS

    GlaxoSmithKline Biologicals S.A.

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule active

    1 trial

  21. PREDNISOLONE, Placebo for Depemokimab Injection, Placebo for Prednisolone

    GlaxoSmithKline Biologicals S.A.

    Hypereosinophilic Syndrome (HES)

    phase 3 small molecule active

    1 trial

  22. Placebo for Belimumab Solution for Injection, 200 mg/mL, Benlysta 200 mg solution for injection in pre-filled syringe.

    GlaxoSmithKline Biologicals S.A.

    systemic sclerosis associated interstitial lung disease

    phase 3 small molecule active

    1 trial

  23. Placebo for Bepirovirsen Solution for Injection 150 mg/mL

    GlaxoSmithKline Biologicals S.A.

    Hepatitis B, Chronic

    phase 3 small molecule active

    1 trial

  24. Placebo for Bepirovirsen Solution for Injection 150 mg/mL

    GlaxoSmithKline Biologicals S.A.

    Hepatitis B, Chronic

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources